127 related articles for article (PubMed ID: 37310848)
1. Targeting c-Jun Is a Potential Therapy for Luminal Breast Cancer Bone Metastasis.
Han Y; Katayama S; Futakuchi M; Nakamichi K; Wakabayashi Y; Sakamoto M; Nakayama J; Semba K
Mol Cancer Res; 2023 Sep; 21(9):908-921. PubMed ID: 37310848
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of highly osteolytic luminal breast cancer cell lines by intracaudal arterial injection.
Han Y; Nakayama J; Hayashi Y; Jeong S; Futakuchi M; Ito E; Watanabe S; Semba K
Genes Cells; 2020 Feb; 25(2):111-123. PubMed ID: 31849141
[TBL] [Abstract][Full Text] [Related]
3. MDA-MB-231 breast cancer cells fuel osteoclast metabolism and activity: A new rationale for the pathogenesis of osteolytic bone metastases.
Lemma S; Di Pompo G; Porporato PE; Sboarina M; Russell S; Gillies RJ; Baldini N; Sonveaux P; Avnet S
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3254-3264. PubMed ID: 28866133
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA 10b promotes abnormal expression of the proto-oncogene c-Jun in metastatic breast cancer cells.
Knirsh R; Ben-Dror I; Modai S; Shomron N; Vardimon L
Oncotarget; 2016 Sep; 7(37):59932-59944. PubMed ID: 27494896
[TBL] [Abstract][Full Text] [Related]
5. Proanthocyanidins attenuate breast cancer-induced bone metastasis by inhibiting Irf-3/c-jun activation.
Guo S; Zhu W; Yin Z; Xiao D; Zhang Q; Liu T; Ni J; Ouyang Z; Xie H
Anticancer Drugs; 2019 Nov; 30(10):998-1005. PubMed ID: 31625993
[TBL] [Abstract][Full Text] [Related]
6. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
7. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
8. Chemokine axes in breast cancer: factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors.
Weitzenfeld P; Kossover O; Körner C; Meshel T; Wiemann S; Seliktar D; Legler DF; Ben-Baruch A
J Leukoc Biol; 2016 Jun; 99(6):1009-25. PubMed ID: 26936935
[TBL] [Abstract][Full Text] [Related]
9. BEX2 has a functional interplay with c-Jun/JNK and p65/RelA in breast cancer.
Naderi A; Liu J; Hughes-Davies L
Mol Cancer; 2010 May; 9():111. PubMed ID: 20482821
[TBL] [Abstract][Full Text] [Related]
10. A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition.
Fang Y; Wang Y; Wang Y; Meng Y; Zhu J; Jin H; Li J; Zhang D; Yu Y; Wu XR; Huang C
Biochem J; 2014 Nov; 463(3):383-92. PubMed ID: 25121353
[TBL] [Abstract][Full Text] [Related]
11. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract][Full Text] [Related]
12. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
13. microRNA-124 inhibits bone metastasis of breast cancer by repressing Interleukin-11.
Cai WL; Huang WD; Li B; Chen TR; Li ZX; Zhao CL; Li HY; Wu YM; Yan WJ; Xiao JR
Mol Cancer; 2018 Jan; 17(1):9. PubMed ID: 29343249
[TBL] [Abstract][Full Text] [Related]
14. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T
J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700
[TBL] [Abstract][Full Text] [Related]
15. Ceramide Kinase Is Upregulated in Metastatic Breast Cancer Cells and Contributes to Migration and Invasion by Activation of PI 3-Kinase and Akt.
Schwalm S; Erhardt M; Römer I; Pfeilschifter J; Zangemeister-Wittke U; Huwiler A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092937
[TBL] [Abstract][Full Text] [Related]
16. DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis.
Wang Y; Lei R; Zhuang X; Zhang N; Pan H; Li G; Hu J; Pan X; Tao Q; Fu D; Xiao J; Chin YE; Kang Y; Yang Q; Hu G
J Clin Invest; 2014 Apr; 124(4):1646-59. PubMed ID: 24590291
[TBL] [Abstract][Full Text] [Related]
17. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications.
Clementz AG; Rogowski A; Pandya K; Miele L; Osipo C
Breast Cancer Res; 2011 Jun; 13(3):R63. PubMed ID: 21679465
[TBL] [Abstract][Full Text] [Related]
18. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
[TBL] [Abstract][Full Text] [Related]
19. A Selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment.
Kang J; Choi YJ; Seo BY; Jo U; Park SI; Kim YH; Park KH
Sci Rep; 2019 Jun; 9(1):8726. PubMed ID: 31217507
[TBL] [Abstract][Full Text] [Related]
20. Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.
Rafiei S; Tiedemann K; Tabariès S; Siegel PM; Komarova SV
Cancer Lett; 2015 Jun; 361(2):262-70. PubMed ID: 25779674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
